Alprolix Disease Interactions
There are 2 disease interactions with Alprolix (coagulation factor ix).
Prothrombin complex (applies to Alprolix) heparin-induced thrombocytopenia
Major Potential Hazard, Moderate plausibility.
The brand name products, Kcentra and Bebulin of prothrombin complex, contain heparin; therefore, their use is contraindicated in patients with known heparin-induced thrombocytopenia.
Prothrombin complex (applies to Alprolix) thromboembolism
Major Potential Hazard, Moderate plausibility. Applicable conditions: Coagulation Defect, Thrombotic/Thromboembolic Disorder, Thrombotic Thrombocytopenic Purpura, Myocardial Infarction, Pulmonary Embolism, Disseminated Intravascular Coagulation
The brand name product, Kcentra of prothrombin complex is contraindicated in patients with disseminated intravascular coagulation (DIC). Both fatal and non-fatal arterial thromboembolic events (including acute myocardial infarction and arterial thrombosis), and venous thromboembolic events (including pulmonary embolism and venous thrombosis) and disseminated intravascular coagulation have been reported with the use of this product in clinical trials and post marketing surveillance. Exercise care if using this product in patients with a history of thromboembolic events.
Switch to professional interaction data
Alprolix drug interactions
There are 9 drug interactions with Alprolix (coagulation factor ix).
Report options
More about Alprolix (coagulation factor ix)
- Alprolix consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous coagulation modifiers
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Hemgenix
Hemgenix (etranacogene dezaparvovec-drlb) is a gene therapy indicated for the treatment of adults ...
Qfitlia
Qfitlia is used for hemophilia a, hemophilia a with inhibitors, hemophilia b, hemophilia b with ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Idelvion
Idelvion (coagulation factor ix recombinant, albumin fusion protein) is a long-acting, injectable ...
Hympavzi
Hympavzi (marstacimab-hncq) may be used to prevent or reduce the frequency of bleeding episodes ...
BeneFix
BeneFix (coagulation factor IX) is a once-weekly, injectable, treatment for hemophilia B that may ...
Rebinyn
Rebinyn (glycopegylated coagulation factor IX [recombinant]) is an injectable, long-lasting, human ...
NovoSeven RT
NovoSeven RT (coagulation Factor VIIa, recombinant) is an injectable, coagulation factor VIIa that ...
Profilnine
Profilnine is used for factor ix deficiency, factor vii deficiency, hemophilia a with inhibitors ...
Fidanacogene elaparvovec
Fidanacogene elaparvovec is used for hemophilia b
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
